New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer

Дата публикации: 24-07-2026 16:00:05

Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to an international phase 3 clinical trial published in The New England Journal of Medicine.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer	5	5	08-07-2026
2	Colon cancer breakthrough keeps patients cancer-free for nearly 3 years	0	10.99	06-05-2026
3	Комбинированная терапия рака почки прошла третью фазу клинических испытаний	0	0	01-08-2025
4	Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer	7	8	01-07-2026
5	New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer	5	7	02-07-2026
6	Tumore del pancreas e melanoma, tra farmaci intelligenti e immunoterapia: speranze per cure sempre più efficaci	0	5.52	03-06-2026
7	New vitamin B12 therapy shows promise against deadly brain cancer	0	10.4	27-06-2026
8	Redesigned lung cancer drug matches tumor control with fewer off-target interactions	0	9.72	24-07-2026
9	Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer	0	11.1	13-07-2026
10	Novel biomarker research offers new hope in the fight against colorectal cancer	7	8	06-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.13. Источник: medicalxpress.com.